Rights Issues Demystified: The Complete Indian Investor’s Guide — Should You Subscribe, Sell Your Rights, or Let Them Lapse?

What Is a Rights Issue — And Why Should Every Indian Investor Understand It?

Imagine you own shares in a company you believe in deeply. One morning, you receive an official notice: the company is offering you the right to buy additional shares — at a discount to the current market price — before it offers them to anyone else. This is a rights issue, and it is one of the most misunderstood corporate actions in the Indian stock market.

FY 2025-26 has been the strongest year for rights issues in over half a decade. More than 120 rights issue announcements have already been recorded this financial year, with total mobilisation potential touching ₹39,439 crore — a staggering 95% increase over FY 2024-25’s ₹20,300 crore. Even Adani Enterprises executed a massive ₹24,930 crore rights issue at a ratio of 3:25 at ₹1,800 per share. Rights issues are no longer a rare event — they are a mainstream capital raising tool that every Indian investor will encounter.

Yet most retail investors freeze when they receive a rights issue notice. They don’t know what to do. Should they subscribe? Should they sell their rights entitlements? Should they simply let the deadline pass? This confusion costs them money — either by missing an excellent opportunity or by blindly putting more capital into a deteriorating business.

Today, we are going to demystify rights issues completely. By the end of this post, you will know exactly how to evaluate any rights issue and make an intelligent decision — like the value investor you are becoming.

How a Rights Issue Works: The Mechanics Explained

When a company needs capital for expansion, debt repayment, or working capital, it has several choices: bank loans, NCDs, QIP (selling to institutions), or raising equity from existing shareholders via a rights issue. A rights issue is essentially the company saying: “Before we go to the market, we want to give our existing loyal shareholders the first opportunity to maintain their ownership stake.”

Here is how the process works step by step:

Step 1 — Board Approval: The company’s board approves a rights issue and announces the ratio (e.g., 1:4 means you can buy 1 new share for every 4 shares you currently hold) and the price (always at a discount to market price, typically 20–40% below current price).

Step 2 — Record Date: SEBI mandates a record date. Only shareholders who hold the stock as of this date are entitled to participate. This is critical — if you buy the stock after the record date, you will not receive rights entitlements.

Step 3 — Rights Entitlement (RE) Shares: Under SEBI’s landmark 2025 reforms, all rights entitlements are now credited directly to your demat account as tradeable instruments (called RE shares) before the subscription window opens. This is a game-changer — it means even if you don’t want to subscribe, you can SELL your rights entitlements on the stock exchange and receive cash for them.

Step 4 — Subscription Window: Shareholders have a 7–30 day window to apply for their entitled shares through their broker or via the company’s registrar (ASBA or UPI mandate). Under SEBI’s 2025 circular, rights issues must now be completed within 23 working days of board approval — dramatically faster than the 317-day average of previous years.

Step 5 — Allotment: Unsubscribed rights may be renounced to others or underwritten. After the window closes, shares are allotted and credited to demat accounts within a few days.

Your Three Choices as a Shareholder — And What Each One Means

Every existing shareholder has exactly three options when a rights issue is announced. Understanding the financial implication of each is essential.

Choice 1: Subscribe (Buy the New Shares)

You use your rights entitlement to purchase the additional shares at the discounted price. This is the right choice when you have high conviction in the business, the company is using funds for value-accretive purposes (expansion, R&D, capacity addition), and the issue price represents genuine value. By subscribing, you maintain your ownership percentage and potentially buy more of a quality business at a discount.

Choice 2: Sell Your Rights Entitlement (RE Shares)

Under SEBI’s 2025 framework, your rights entitlements are credited as tradeable RE shares in your demat. You can sell them on the exchange during the subscription window and receive cash. The RE share price typically reflects the theoretical value of the right: the difference between the current market price and the issue price, adjusted for the entitlement ratio. This is the right choice when you lack conviction in the business, need liquidity, or have a better use for the capital.

Choice 3: Let the Rights Lapse (Do Nothing)

This is almost always the worst choice. If you neither subscribe nor sell your RE shares, your entitlement simply expires. You receive nothing, and your ownership stake in the company gets diluted by the new shares issued to other subscribers. Your existing shares become worth less per share (the post-rights price is lower than the pre-rights price due to dilution). Letting rights lapse is literally gifting value to other investors.

How to Evaluate Any Rights Issue: A 5-Point Framework

Not all rights issues are created equal. Some are excellent opportunities; others are traps. Here is the 5-point framework value investors use to evaluate them.

Point 1 — Why is the company raising money? This is the most important question. Read the Letter of Offer carefully. Is the capital going toward capacity expansion, R&D, acquisitions, or new product lines? These are value-creating uses. Or is the company raising money to repay existing debt, fund operating losses, or bail out promoters? These are red flags. Companies raising capital to grow from a position of strength are very different from companies raising capital out of desperation.

Point 2 — Is the business fundamentally strong? Apply the same quality filters you use for any stock purchase. Look at ROCE (ideally above 15%), ROE (above 15%), debt levels, cash flow from operations, and revenue growth. A rights issue in a strong business is an opportunity. A rights issue in a weak business compounds your losses.

Point 3 — What is the issue price vs. intrinsic value? The issue price is always below market price, but is market price itself fair? Calculate the Theoretical Ex-Rights Price (TERP) — the expected market price after the rights issue accounting for dilution. TERP = (Market Cap before rights + New capital raised) ÷ (Total shares after rights). If TERP is still below your estimate of intrinsic value, subscribing creates value. If TERP exceeds intrinsic value, even the discounted issue price is expensive.

Point 4 — Promoter participation signals conviction. Are the promoters subscribing to their full entitlement? If promoters are subscribing (or even renouncing rights to raise their stake where SEBI permits), it signals they believe the business has strong future prospects. If promoters are selling their RE shares or are suspiciously absent from the subscription, treat this as a yellow flag.

Point 5 — What is the dilution impact? Calculate the new total share count after the rights issue. A 1:1 rights issue doubles the share count, which means EPS gets halved unless profits grow proportionately. Ensure that the new capital being raised will generate returns that compensate for the dilution. A business earning 20% ROCE can absorb dilution much better than one earning 8%.

Real Examples from Indian Markets

Rights issues have played a pivotal role in the Indian market’s biggest success stories. Reliance Industries has executed multiple rights issues over the decades, each time deploying capital into transformative new businesses. The 2020 Reliance Rights Issue (1:15 ratio at ₹1,257 per share) raised ₹53,125 crore — the largest rights issue in Indian corporate history at the time — and funded the company’s digital and retail transformation. Shareholders who subscribed and held have been handsomely rewarded.

In contrast, rights issues by companies with deteriorating fundamentals — those with rising NPA levels, promoter pledging, or weak operating cash flows — have often resulted in permanent capital destruction. The lesson is clear: the business quality must come first.

As of FY 2025-26, with SEBI’s streamlined framework (23-working-day completion timeline, RE shares tradeable on exchanges, simplified documentation), rights issues are becoming faster, more transparent, and more investor-friendly. The 95% year-on-year jump in fundraising via rights issues to ₹39,439 crore reflects this renewed confidence.

Red Flags in Rights Issues — When to Run

Not every rights issue deserves your capital. Watch for these warning signs: first, repeated rights issues at short intervals, which suggests the business consistently burns more cash than it generates and cannot fund itself organically; second, a very aggressive dilution ratio (e.g., 3:1 or higher) with vague use-of-proceeds disclosures; third, issue price that is barely below market price (suggesting the discount is cosmetic, not a genuine opportunity); fourth, declining ROCE or ROE trends despite multiple capital raises; and fifth, promoters pledging shares while simultaneously raising more equity — a classic value trap signal.

A company that is consistently growing, generating free cash flow, and has a clear, well-documented use of proceeds is the kind of business where a rights issue is an opportunity to add more at a discount.

The Titan Biotech Lesson: Quality Businesses Don’t Need Desperation Capital Raises

One of the most important things to understand about genuinely high-quality businesses is that they rarely need to raise equity capital from shareholders. Companies like Titan Biotech Ltd (BSE: 524717) — currently trading at ₹504, at its 52-week high with a market cap of ₹2,082 crore — generate strong internal cash flows. With a ROCE of 16.9% and ROE of 15.0% on a completely debt-free balance sheet, Titan Biotech does not need to dilute shareholders to fund its operations.

This is the power of identifying quality compounders early: you invest in businesses that grow on their own steam, compound your wealth over time, and never come back to you asking for more capital. The SENSEX is at 73,319 and NIFTY at 22,713 as of the last trading session — both in modestly positive territory — and through all market cycles, quality businesses with strong fundamentals have delivered superior returns to patient investors.

When evaluating a rights issue, always ask yourself: would a business of this quality even need to do a rights issue? The answer tells you a great deal about the business’s underlying economics.

The 90% Rule — Why F&O Traders Miss All of This

SEBI’s own data shows that 9 out of 10 individual traders in the equity Futures & Options segment incur net losses. F&O trading is essentially gambling with leverage — it produces no economic value and destroys wealth at an alarming rate. A rights issue is a corporate governance event that requires careful fundamental analysis, long-term thinking, and patient capital allocation — the exact opposite of what the F&O mindset encourages.

As a value investor, you possess a massive structural advantage: you evaluate businesses, not price ticks. Rights issues are one of the most concrete, actionable opportunities where this fundamental thinking pays off directly. The investor who understands the Theoretical Ex-Rights Price, the use of proceeds, the business quality, and the promoter’s conviction will always make a better decision than the one who simply reacts to the price chart.

To learn the complete framework for identifying value investing opportunities like this — and many more — explore our free Value Investing Course Playlist on YouTube.

Key Takeaways — Rights Issues Simplified

A rights issue is an offer by a company to its existing shareholders to buy new shares at a discount before offering them to the public. You have three choices: subscribe (buy), sell your RE entitlement (cash out the discount), or let it lapse (almost always a mistake). The single most important question is why the company needs the capital — growth from strength versus desperation to survive. The SEBI 2025 reforms have made rights issues faster (23 working days), more transparent, and more liquid (RE shares tradeable on exchanges). Use the 5-point framework: purpose of capital, business quality, TERP vs intrinsic value, promoter participation, and dilution impact. Quality businesses with strong ROCE and free cash flow generation rarely need to come back to shareholders for capital — companies like Titan Biotech prove this principle every day.

SEBI Disclaimer: 9 out of 10 individual traders in the equity Futures & Options segment incurred net losses according to a SEBI study. F&O trading is essentially gambling. Focus on quality stock picking and long-term value investing instead.

Disclaimer: The author (Manish Goel) is a SEBI Registered Research Analyst (Registration No. INH100004775) and Multibagger Shares (Multibagger Securities Research & Advisory Pvt. Ltd.) is a SEBI Registered Investment Advisor (Registration No. INA100007736). This post is for educational purposes only and should not be construed as a buy/sell recommendation. Please do your own research and consult a qualified financial advisor before making investment decisions. Stock market investments are subject to market risks. Past performance is not indicative of future results.

Manish Goel

Manish Goel is a Chartered Accountant, SEBI-registered Investment Advisor, and founder of Multibagger Shares. A full-time value investor since 2010, he has helped thousands of investors build long-term wealth through quality stock picking and disciplined fundamental analysis.

See Full Bio